Table 5.

Associations of CYP19 haplotypes with risk of breast cancer based on SNPs selected using the LD-tag approach of Carlson^a

Hap #	5'FR Exon 1.1 (−588)	5'FR Exon 2a (−468)	5’FR Exon I.5 (−628)	Intron 1.7 54	5'FR Exon I.f (−725)	5'FR Exon 1.2 (−596)	5'FR Exon 1.6 (−196)	Intron 2 (−59)	Intron 4 27	Exon 5 602	Intron 7 26	3'UTR 1673	Hap. Freq.b	Score Testc	P Valued
1	G	C	G	G	G	T	C	T	INS	C	T	T	0.018	−2.468	0.014
2	G	C	C	G	A	C	A	T	DEL	C	C	T	0.081	−1.215	0.224
3	G	C	C	C	G	C	A	T	INS	C	C	G	0.037	−1.202	0.229
4	G	C	G	G	G	T	A	T	DEL	C	C	T	0.063	−1.001	0.317
5	G	C	G	G	G	T	C	C	INS	C	C	G	0.335	−0.810	0.418
6	A	C	G	G	G	T	A	T	DEL	C	C	G	0.030	−0.432	0.666
7	A	C	G	G	G	T	A	C	INS	T	C	G	0.027	−0.088	0.930
8	A	C	G	G	G	T	C	C	INS	C	C	G	0.022	0.193	0.847
9	G	T	G	G	G	T	C	T	INS	C	T	T	0.044	0.329	0.743
10	G	C	G	G	G	T	A	T	DEL	C	C	G	0.120	1.110	0.267
11	G	T	G	G	G	T	C	C	INS	C	C	G	0.114	1.452	0.147
12	A	C	G	G	G	T	C	T	INS	C	T	T	0.019	1.500	0.133

^aResults adjust for the effects of age, region of residence at entry into study, age at menarche, menopause status, education, activity, family history of breast and/or ovarian cancer, and alcohol intake. Selection parameters: 0.05 minor allele frequency, 80% correlation within bins. Global test of association: p=0.10.

^bEstimated haplotype frequency

^cScore statistic comparing the haplotype of interest to all other haplotypes combined. Negative values imply decreased risk of breast cancer, positive values imply increased risk.

^dP-value comparing the haplotype of interest to all other haplotypes combined.